Pay in 4 interest-free payments of $7.10 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies
Insights may cover the historical clinical development of Glucagon-like Peptide-1 (GLP-1) Agonists, their mechanism of action, their subtypes and future commercial prospects
& Nau, C
As of the April approval, Lilly cited its own internal data suggesting that fewer than 1 in 10 people who could medically benefit from a GLP-1 medication were taking one
The pharmaceutical industry currently has very few approved treatments for metabolic-associated steatotic liver disease
In 2016, concerns regarding retinopathy associated with GLP-1 were first raised in the Semaglutide Unabated Sustainability in Treatment of T2DM (SUSTAIN) 6 trial with semaglutide [89]
US$ 28.59
US$ 22.73
US$ 20.29
US$ 29.93
US$ 22.96
US$ 29.81
